# Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

> **NCT07085169** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Colo-rectal Cancer
- Third-line and Beyond Therapy
- TAS 102
- Bevacizumab

## Interventions

- **DRUG:** Trifluridine/tipiracil (TAS-102) plus bevacizumab

## Key facts

- **NCT ID:** NCT07085169
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085169, "Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07085169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*